Brand Reference: Bystolic
| Metric | Verified Benchmark | Source |
|---|---|---|
| Nebivolol Hydrochloride RxNorm Concept ID | 31555 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $148.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $9.40 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $12.00 / mo | 24 Zero-PHI Verified Patient Logs |
Racemic d/l-enantiomer pair combining ultra-high beta-1 adrenergic selectivity (d-nebivolol) with endothelial beta-3 agonist stimulation of endothelial nitric oxide synthase (l-nebivolol)—lowering central aortic pressure without inducing insulin resistance or erectile dysfunction.
For self-pay patients filling Nebivolol Hydrochloride (NDC 00456-1405-30), direct wholesale and telehealth fulfillment drops monthly spend from $148.00 retail to $9.40 (94% savings against a $0.2100 CMS pharmacy acquisition baseline).
Clinical clearance of Nebivolol Hydrochloride (Cardioselective Beta-1 Blocker & Endothelial eNOS Nitric Oxide Enhancer) relies on hepatic cyp2d6 aromatic hydroxylation and glucuronidation with a 12 hours (CYP2D6 extensive metabolizers) / 19 hours (poor metabolizers) half-life; patients absorbing at 12%–96% (active hydroxylated metabolites compensate phenotype) bioavailability typically observe target onset around 1.5–4 hours peak hemodynamic effect.
FDA clinical labeling for Nebivolol Hydrochloride restricts administration in severe sinus bradycardia (< 50 bpm); second- or third-degree av block without pacemaker; decompensated cardiogenic shock across 2.5 mg PO daily, 5 mg PO daily, 10 mg PO daily, 20 mg PO daily, with self-reported patient tracking dominated by resting hr -8 bpm (14% of reports), mild fatigue (week 1) (7% of reports).
Across 24 verified cash-pay logs, Nebivolol Hydrochloride achieves a 92.00% Worth-It rating with out-of-pocket spend averaging $12.00/mo versus $148.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 2.5 mg PO daily for Nebivolol Hydrochloride; monthly out-of-pocket dropped to $8.27 compared with $148.00 retail.
Completed 10 weeks on Nebivolol Hydrochloride (5 mg PO daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 10 mg PO daily Nebivolol Hydrochloride sourced via TeleMed ($10.90/mo cash pay without insurance prior authorization).